PierianDx and Biodesix Partner to Advance Lung Cancer Diagnostics
19 1월 2022 - 11:15PM
Business Wire
Partnership enables comprehensive clinical
information to deliver optimal patient care
PierianDx, the global leader in clinical genomics knowledge,
today announced that it has partnered with Biodesix to provide its
interpretation technology platform for use with the Biodesix newly
launched GeneStrat NGS™ genomic test, a blood-based tumor profiling
test to detect actionable mutations in patients with non-small cell
lung cancer (NSCLC). Biodesix (Nasdaq: BDSX) will use the PierianDx
platform to provide clear, up-to-date clinical interpretations for
mutations detected by the GeneStrat NGS test as part of patient
test results used by physicians to help inform a personalized
treatment strategy and facilitate monitoring in lung cancer.
The GeneStrat NGS test is a key part of the IQLung™ testing
strategy, designed to measure tumor-specific mutations and patient
immune profiles with results in an unprecedented 72 hours so that
physicians can assess overall prognosis and personalize treatment
plans. The IQLung strategy uses genomic profiling to detect
actionable mutations in lung cancer, such as EGFR, ALK, KRAS, MET,
NTRK, ERBB2, and others, and delivers them in an expedited
timeframe so patient treatment can begin sooner.
The GeneStrat NGS test data will be analyzed and interpreted
using the most current therapy approvals and oncology guideline
recommendations and delivered in a physician-ready report. The
technology is backed by a comprehensive clinical knowledgebase and
adaptive learning algorithms that take disparate inputs and
translate them into concise interpretations with supporting
evidence. As a result, characteristics of patient variants, even
though rare or novel, are leveraged to present the most optimal
treatment possibilities.
“We are helping to meet an unmet need in the continuum of care
for lung cancer,” said Scott Hutton, CEO of Biodesix. “Partnering
with PierianDx not only helps to deliver rapid results to
physicians, but it also gives them information that can be easily
interpreted and actioned, supporting them in providing precision
care for their patients.”
“We are thrilled to provide our interpretation technology to
support the outstanding testing solution from Biodesix to treat
patients with lung cancer,” states Mark McDonough, CEO of
PierianDx. “We are committed to democratizing clinical genomics
globally and this partnership with Biodesix supports our vision to
broaden access to genomic testing and provide precision care to
patients everywhere.”
About PierianDx
PierianDx is a partner in precision medicine, enabling
clinicians and medical facilities to advance clinical genomics
programs and modernize patient care. We believe in the potential of
genomics to transform human health and are working to ensure that
communities anywhere can experience the benefits. With advanced
interpretation technology connected to the most comprehensive
genomic knowledgebase, PierianDx empowers providers with genomic
insights to fulfill the promise of precision care. For more
information, visit www.pieriandx.com.
About Biodesix
Biodesix is a leading data-driven diagnostic solutions company
with a focus in lung disease. The Company develops diagnostic tests
addressing important clinical questions by combining multi-omics
through the power of artificial intelligence. Biodesix is the first
company to offer eight non-invasive tests for patients with lung
diseases. The blood based Nodify Lung® nodule risk assessment
testing strategy, consisting of the Nodify XL2® and the Nodify CDT®
tests, evaluates the risk of malignancy in incidental pulmonary
nodules, enabling physicians to better triage patients to the most
appropriate course of action. The blood based IQLung™ strategy for
lung cancer patients integrates the GeneStrat® targeted test, the
GeneStrat NGS™ test and the VeriStrat® test to support treatment
decisions across all stages of lung cancer with results in 36-72
hours, expediting time to treatment. Biodesix also leverages the
proprietary and advanced Diagnostic Cortex® AI (Artificial
Intelligence) platform, to collaborate with many of the world’s
leading biotechnology and pharmaceutical companies to solve complex
diagnostic challenges in lung disease. Biodesix launched the
SARS-CoV-2 ddPCR™ test, the Platelia SARS-CoV-2 Total Ab, and the
cPass™ SARS-CoV-2 Neutralization Antibody test (cPass™
Neutralization Test Kit, GenScript, Inc,) in response to the global
pandemic and virus that impacts the lung and causes COVID-19. For
more information about Biodesix, visit biodesix.com.
Note Regarding Forward-Looking Statements
This press release may contain forward-looking statements that
involve substantial risks and uncertainties for purposes of the
safe harbor provided by the Private Securities Litigation Reform
Act of 1995. All statements contained in this press release other
than statements of historical fact, are forward-looking statements.
The words “believe,” “may,” “will,” “estimate,” “continue,”
“anticipate,” “intend,” “plan,” “expect,” “predict,” “potential,”
“opportunity,” “goals,” or “should,” and similar expressions are
intended to identify forward-looking statements. Such statements
are based on management’s current expectations and involve risks
and uncertainties. Actual results and performance could differ
materially from those projected in the forward-looking statements
as a result of many factors. Biodesix has based these
forward-looking statements largely on its current expectations and
projections about future events and trends. These forward-looking
statements are subject to a number of risks, uncertainties, and
assumptions. Forward-looking statements may include information
concerning the impact of the COVID-19 pandemic on Biodesix and its
operations, it is possible or assumed future results of operations,
including descriptions of its revenues, profitability, outlook, and
overall business strategy. Forward-looking statements are
inherently subject to risks and uncertainties, some of which cannot
be predicted or quantified. Factors that could cause actual results
to differ materially from those contemplated in this press release
can be found in the Risk Factors section of Biodesix’s most recent
annual report on Form 10-K, filed March 16, 2021, or subsequent
quarterly reports on Form 10-Q during 2021, if applicable. Biodesix
undertakes no obligation to revise or publicly release the results
of any revision to such forward-looking statements, except as
required by law. Given these risks and uncertainties, readers are
cautioned not to place undue reliance on such forward-looking
statements. All forward-looking statements are qualified in their
entirety by this cautionary statement.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20220119005186/en/
Lisa Owen lowen@pieriandx.com
Biodesix (NASDAQ:BDSX)
과거 데이터 주식 차트
부터 6월(6) 2024 으로 7월(7) 2024
Biodesix (NASDAQ:BDSX)
과거 데이터 주식 차트
부터 7월(7) 2023 으로 7월(7) 2024